Search Results
193 items found for "Glaxo Inc"
- Ep 41 with Dr. Terry Kenakin
Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome
- Ep 44 with Dr. Steven Foord
Steven Foord Steve Foord trained as a Physiologist and Pharmacologist and worked for Glaxo through to These included the identification of RAMPs (solving some CGRP family issues) and the GABA B, carboxylic
- Removing the GPCR-mediated brake on exocytosis enhances insulin action, promotes adipocyte browning, and protects against diet-induced obesity
She oversaw an increase of the size of the Department, as well as a quintupling of its NIH funding, in Current areas of interest include Protease Activated Receptor signaling in the cardiovascular system She has received numerous awards, including the Glaxo Cardiovascular Discovery Award, the Distinguished
- Ep 96 with R. Scott Struthers
Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions
- Ep 60 with Dr. Josephine (Pina) Cardarelli
Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. Prior to this, she held the position of Vice President, at Medarex, Inc . While at BMS and Medarex, she led programs from target ID to clinical development that included, CXCL10 She is an inventor on 39 issued U.S. patents including anti-PD-1 patents, 22 EP patents, and greater
- Ep 76 with Steve McCloskey
After graduating from UCSD he founded Nanome Inc to build Virtual Reality solutions for Scientists and
- Ep 137 with Dr. Josh Pottel
Josh Pottel "I lead Molecular Forecaster Inc.
- Ep 58 with Dr. Juan José Fung
Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused
- Biased agonism at the GLP-1 receptor: from structure to animal models of disease
Sexton’s awards include the ASCEPT Lecturer award, Endocrine Society (Australia) Senior Plenary award Sexton is also a co-founder of Septerna Inc. " Patrick Sexton on the web CCeMMP Monash University Dr.
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
(2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics North America Inc discovery of small molecules for the treatment of inflammatory disorders and cancer at Paraza Pharma Inc Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3. pharmacological targets and contribute to the development of innovative treatments for a range of diseases, including
- A journey from Duke to McGill along the dopamine circuit
doctoral training at the Pierre and Marie Curie University in Paris and a short internship at Genentech Inc
- Ep 89 with Dr. Patrick Sexton
Sexton’s awards include the Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists Sexton is also a co-founder of the San Francisco-based biotechnology company Septerna Inc . Dr.
- Ep 106 with Dr. Bruno Giros
doctoral training at the Pierre and Marie Curie University in Paris and a short internship at Genentech Inc with an H factor of 79 and 32,000 citations (Google Scholar) and has received several distinctions, including
- The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
These include EP2, EP4, A2AR, β1AR and β2AR, all of which promote T cell dysfunction. The Author(s), under exclusive licence to Springer Nature America, Inc."
- DANGER Signals Activate G-Protein Receptor Kinases Suppressing Neutrophil Function and Predisposing to Infection After Tissue Trauma
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved."
- Severity of neurological long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors
News < GPCRs in Oncology and Immunology Severity of neurological long-COVID symptoms correlates with increased Methods: This monocentric, cross-sectional study included patients who suffered a mild to moderate SARS-CoV Conclusions: Concentrations of autoantibodies correlates to intensity of neurological disorders including
- Esophageal and gastric cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004 to 2018
< GPCR News < GPCRs in Oncology and Immunology Esophageal and gastric cancer incidence trends in Golestan Data on incident cases of EC and GC during 2004 to 2018 were obtained from the Golestan Population-based The age-standardized incidence rates (ASRs) were calculated and presented per 100 000 person-years. We also fitted age-period-cohort (APC) models to assess nonlinear period and cohort effects as incidence We found significant decreasing trends in incidence rates of EC (EAPC = -5.0; 95% CI: -7.8 to -2.2) and
- Colorectal cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004-2018
< GPCR News < GPCRs in Oncology and Immunology Colorectal cancer incidence trends in Golestan, Iran: 2004-2018 Published date July 11, 2023 Abstract " Background: We investigated the effects of factors including age, birth year (cohort) and diagnosis year (period) on colorectal cancer (CRC) incidence trends in Methods: We obtained data on incidence cases of CRC from the Golestan Population-based Cancer Registry Our findings suggested significantly increasing trends in CRC incidence rates from 2004 to 2018 (EAPC
- Delivery of US28 by incoming HCMV particles rapidly attenuates Akt activity to suppress HCMV lytic replication in monocytes
< GPCR News < GPCRs in Oncology and Immunology Delivery of US28 by incoming HCMV particles rapidly attenuates
- Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19
< GPCR News < GPCRs in Oncology and Immunology Increased protease-activated receptor 1 autoantibodies associated with severe COVID-19 Published date December 27, 2022 Abstract In patients with severe #COVID19 , increased
- Posters | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Ductal carcinomas are increasingly diagnosed but identifying which will progress to invasive disease ) within patient luminal carcinoma samples exhibiting non-invasive or invasive features, the latter including mouse model will be useful to delineate the collecting duct-specific role of GPR56 for renal function, including GPR110 knockout (KO) mice displayed trends for increased anxiety-like behaviors in the elevated plus The y-maze showed a significant sex by genotype interactions with GPR110 KO male mice having increased
- Full Agenda for Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Van Meir Adhesion GPCR BAI1/ADGRB1 can block IGF1R-mediated growth signalling, increase radiosensitivity
- Advanced data analysis for GPCR pharmacology
The participants will increase their ability to perform, understand, and communicate GPCR pharmacology The increased understanding will also be helpful for the participants in their training and education Sessions will include a one-hour live lecture plus one hour of Q&A and discussion.
- Principles of Pharmacology in Drug Discovery II
describes essential additional elements to GPCR discovery programs that extend the discovery process and increase Sessions will include a 1-hour live lecture plus 30 minutes of Q&A.
- Principles of Pharmacology in Drug Discovery I
Sessions will include a 1-hour live lecture plus 30 minutes of Q&A.
- Applying Pharmacology to Drug Discovery
Sessions will include a 1-hour live lecture plus 30 minutes of Q&A.
- Session VIII | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
physiologic/pathologic function in the heart in an effort to uncover novel therapeutic directions for HF, including
- Session VIII * | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
The change in protein expression of key proteins including VEGFA is associated with the abnormal renal mutants, similar to starved wild-type cells, upregulate various extracellular matrix-related genes, including